Hsp90 inhibition has been shown to decrease BCL-6 levels due to protein instability, leading to the activation of target genes (ATR and TP53) and the apoptosis of lymphoma cells, showing that the Hsp90–BCL-6 interaction is crucial for lymphoma survival (56). The gene discussed is TP53; the disease is lymphoma.